$31 billion flowed into healthcare startups in six months, and most of it went to the companies that engineered their market first

HSBC Innovation Banking just published its mid-year venture healthcare report, and where the money is flowing should stop every medtech founder cold.

By Omar Khateeb, CEO of MarketCraft

HSBC Innovation Banking · Mid-Year 2026 · free, no email required

The rebound comes with a catch

HSBC summed the market up in one word. Fearless.

Investors are taking real risk again, AI has pulled fresh money into the market, and exits are finally handing people returns.

The capital is back, but it is not spreading out.

It is concentrating into a small group of companies that made themselves easy to believe in before they ever needed the check.

What jumped out in the data

Healthcare venture put up $31B across 1,101 deals in the first half. HSBC has the full year on pace for $65 to $70B, ahead of last year's $59B.

Mega rounds are the whole story. Financings of $100M or more have taken close to 60% of all healthcare dollars for three years running.

In early-stage biopharma it is starker still. The top 10% of deals now take 63% of first-financing dollars.

Biopharma still owns half the money, led by a $450M Phase III oncology round. And acquirers bought 19 pre-clinical or Phase I biotechs in the last 18 months, at a median of $1B upfront.

Med device saw 24 financings over $50M as bigger Series A rounds returned.

HealthTech pulled $9.3B across 391 deals. Provider operations led at $3.3B, and WHOOP's $575M round headlined a surge in consumer health.

The exit window cracked open too. Six medtech IPOs priced in 18 months at a median of +4%, and AI buyers paid $400M for a venture-backed life science tools company.

What it means for founders

Read past the optimism and the report is describing a barbell.

Money is pouring into a handful of perceived winners while everyone else fights over what is left. HSBC's own phrase for it is more money to fewer bets.

Look closely at who is winning. The best technology in the room rarely takes the round. The companies that win are the ones whose category, and their place in it, was obvious to an investor or an acquirer before the conversation started.

The market was already pulling them forward.

For most medtech founders the capital is out there. What they are missing is a market that understands what they do and why it matters.

AI raises the bar here. Every sector is now flooded with AI-enabled companies, so shipping a model no longer sets you apart. The winners built the AI, then engineered a market around it, so the money knew exactly what it was buying.

Maybe you are reading this wondering why the capital and the acquirers keep flowing to companies you know you can out-build.

That gap is the work. Great companies do not wait for the market to form. They engineer it, and the funding follows.

Figures from the HSBC Innovation Banking Venture Healthcare Report, Mid-Year 2026, lead author Jonathan Norris, Managing Director. Data as of June 30, 2026, sourced by HSBC from PitchBook and company filings.